INKT MINK THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, MINK THERAPEUTICS INC reported revenue of n/a, net income of −$3.13M and diluted EPS of −$0.62; for the fiscal year ended December 2025 revenue was n/a.
INKT annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$12.6M, net income −$12.5M (margin n/a), EPS −$2.93
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$11.3M, net income −$10.8M (margin n/a), EPS −$2.86
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$22.9M, net income −$22.5M (margin n/a), EPS −$6.54
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$30.9M, net income −$28.0M (margin n/a), EPS −$0.83
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$28.4M, net income −$30.2M (margin n/a), EPS −$1.16
INKT quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$3.13M, EPS −$0.62
- Quarter ended Mar 31, 2026: revenue n/a, net income −$2.74M, EPS −$0.57
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$2.60M, EPS −$0.52
- Quarter ended Sep 30, 2025: revenue n/a, net income −$2.89M, EPS −$0.65
- Quarter ended Jun 30, 2025: revenue n/a, net income −$4.24M, EPS −$1.06
- Quarter ended Mar 31, 2025: revenue n/a, net income −$2.77M, EPS −$0.70
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$2.46M, EPS −$0.57
- Quarter ended Sep 30, 2024: revenue n/a, net income −$1.81M, EPS −$0.46
- Quarter ended Jun 30, 2024: revenue n/a, net income −$2.70M, EPS −$0.73
- Quarter ended Mar 31, 2024: revenue n/a, net income −$3.81M, EPS −$1.10
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$5.46M, EPS −$6.04
- Quarter ended Sep 30, 2023: revenue n/a, net income −$5.12M, EPS −$0.15
- Quarter ended Jun 30, 2023: revenue n/a, net income −$6.20M, EPS −$0.18
- Quarter ended Mar 31, 2023: revenue n/a, net income −$5.69M, EPS −$0.17
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$7.77M, EPS −$0.23
- Quarter ended Sep 30, 2022: revenue n/a, net income −$6.33M, EPS −$0.19
- Quarter ended Jun 30, 2022: revenue n/a, net income −$6.11M, EPS −$0.18
- Quarter ended Mar 31, 2022: revenue n/a, net income −$7.78M, EPS −$0.23
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$5.76M, EPS −$0.15
- Quarter ended Sep 30, 2021: revenue n/a, net income −$14.3M, EPS −$0.59
INKT cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$5.93M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$9.56M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$15.8M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$18.9M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$12.8M, share buybacks n/a
INKT balance sheet
- Jun 30, 2026: cash $8.81M, total assets $9.62M, total liabilities n/a, shareholders' equity −$14.0M
- Mar 31, 2026: cash $9.53M, total assets $10.4M, total liabilities n/a, shareholders' equity −$12.7M
- Dec 31, 2025: cash $13.4M, total assets $14.2M, total liabilities n/a, shareholders' equity −$14.2M
- Sep 30, 2025: cash $9.50M, total assets $15.0M, total liabilities n/a, shareholders' equity −$13.5M
- Jun 30, 2025: cash $1.68M, total assets $2.48M, total liabilities n/a, shareholders' equity −$25.2M
- Mar 31, 2025: cash $3.23M, total assets $4.27M, total liabilities n/a, shareholders' equity −$21.8M
- Dec 31, 2024: cash $4.58M, total assets $5.72M, total liabilities n/a, shareholders' equity −$19.6M
- Sep 30, 2024: cash $6.33M, total assets $7.37M, total liabilities n/a, shareholders' equity −$17.6M
Is INKT profitable?
No. MINK THERAPEUTICS INC lost $11.4M over the last four quarters.
What is INKT's EPS?
Diluted earnings per share over the last four quarters were −$2.36; −$0.62 in the latest quarter.